L26/O-033 To re-biopsy or not? Diagnostic and clinical implications of segmental abnormalities detected by PGT-A
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.033 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von R. Abramov und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Does re-biopsy after PGT-A refine the chromosomal classification of blastocysts with segmental aneuploidy and identify embryos suitable for transfer? Summary answer Re-biopsy of blastocysts with segmental abnormalities after PGT-A enables reclassification to mosaic in considerable number of cases, expanding transfer eligibility and supporting personalized embryo selection. What is known already Segmental chromosomal abnormalities detected by PGT-A show lower diagnostic concordance than whole-chromosome aneuploidies and are thought to frequently reflect biological mosaicism and technical variability. Previous studies have reported that re-biopsy of embryos with segmental abnormalities can lead to reclassification, often identifying mosaic or euploid results. Transfers of embryos reclassified as mosaic, particularly those with low-level abnormalities, have been associated with significant implantation and good pregnancy outcomes. However, available data are limited, heterogeneous, and the clinical utility of re-biopsy remains insufficiently defined. Study design, size, duration This retrospective, REB-approved study was conducted at a single fertility Centre and its reproductive genetics laboratory from January 2019 to December 2025. High-resolution NGS was used for PGT-A (10 Mb CNV resolution; 30–70% mosaicism). A total of 2,093 blastocysts with segmental abnormalities (out of 55,894 embryos tested) from 1,687 cycles and 1,592 patients were included Participants/materials, setting, methods Mean ovum and sperm provider ages were 32.5 ± 5.3 and 38.9 ± 6.3 years. Overall, 499 embryos (380 patients, 394 cycles) underwent re-biopsy and PGT-A analysis. Primary outcome was concordance with the initial biopsy. Secondary outcomes included associations with blastulation timing (D5–D7), blastocyst grade (GOOD, FAIR, POOR), chromosome type (SUBMETACENTRIC-SMC, METACENTRIC-MC, ACROCENTRIC-AC, SEX CHR-SC), and aberration size (full/partial arm loss/gain). Implantation rates after transfer of reclassified embryos were evaluated. Main results and the role of chance SA after PGT-A was diagnosed in 3.7% of embryos (2,093/55,894). Frequency increased with day of biopsy (D5: 2.3%, D6: 3.9%, D7: 5.4%, p = 0) and embryo quality (GOOD: 1.5%, FAIR: 3.0%, POOR: 5.4%, p = 0). Segmental losses (SL) and gains (SG) of SMC chromosomes constituted 67.7% (n = 1,418) of SA; 20.0% (n = 418) were MC, 5.5% (n = 115) AC, 3.0% (n = 63) SC, and 3.8% (n = 79) involved ≥2 chromosomes (p = 0). SL predominated over SG (72.5% vs 27.5%, p = 0), a pattern consistent across chromosome types: SMC 73.1% vs 26.9%, MC 72.8% vs 27.2%, AC 65.7% vs 34.3%, SC 73.6% vs 26.4% (p = 0). After re-biopsy, 13.4% (n = 76) were reclassified as mosaic loss and 12.5% (n = 71) as mosaic gain, suitable for transfer; 60.6% (n = 343) remained abnormal. Eleven embryos (11.8%, n = 67) did not survive thaw and 1.6% (n = 9) had no intact DNA. Reclassification to mosaic was highest in AC (44.1%) vs SMC, MC, and sex chromosomes (26.4%, 22.3%, 23.5%). Full concordance was higher in SL than SG (54.5% vs 15.0%, p = 0), whereas SG were more often reclassified as mosaic (61.1% vs 18.4%, p = 0). Among 29 transfers, 3 live births and 5 ongoing pregnancies occurred (27.6%). Limitations, reasons for caution The main limitation was the retrospective study design and the limitation of NGS based PGT-A to determine the biological origin of segmental aneuploidy with conclusions based on copy number profiles rather than direct biological confirmation. Wider implications of the findings Comprehensive chromosomal analysis demonstrated that re-biopsy was informative in 87% of embryos. Re-biopsy reclassified 26.0% of embryos with SA as mosaic and suitable for transfer. SA involving AC and SG were more frequently reclassified as mosaic (44.1% and 61.1%), supporting the clinical usability of these embryos and guiding clinical management. Trial registration number No
Zitieren
APA
Abramov, R., Madjunkov, M., Librach, C., & Madjunkova, S. (2026). L26/O-033 To re-biopsy or not? Diagnostic and clinical implications of segmental abnormalities detected by PGT-A. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.033
Vancouver
Abramov R, Madjunkov M, Librach C, Madjunkova S. L26/O-033 To re-biopsy or not? Diagnostic and clinical implications of segmental abnormalities detected by PGT-A. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.033
BibTeX
@article{Abramov2026,
author = {Abramov, R. and Madjunkov, M. and Librach, C. and Madjunkova, S.},
title = {L26/O-033 To re-biopsy or not? Diagnostic and clinical implications of segmental abnormalities detected by PGT-A},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.033}
}
EUVIMED